32results about How to "Strong target specificity" patented technology

The invention discloses a biosensor based on an aptamer and a manufacturing method and application thereof and belongs to the field of biochemical technique. According to the biosensor based on the aptamer, n-octadecyl mercaptan is automatically assembled on a gold film, the n-octadecyl mercaptan is combined with carboxyl group graphene oxide through intermolecular force, activating treatment is carried out on the carboxyl group graphene oxide to enable carboxyl to be converted into an active ester group, and an amido bond is formed through the active ester group and amino acid on molecule of the aptamer to enable the aptamer to be fixed on the surface of the carboxyl group graphene oxide. According to the biosensor based on the aptamer, the electrochemical activity is good, the aptamer can be well fixed, and the biosensor can be used for detection of various kinds of target protein and can be applied to the fields such as biomedicine, food safety and environmental monitoring. The manufacturing method of the biosensor based on the aptamer is simple and easy to operate. Due to the fact that hydroxyl and epoxy group which are on the graphene oxide are converted into the carboxyl due to the adoption of NaOH and ClCH2COONa, the COOH functional group content is high, the good electrochemical activity is achieved, and the aptamer can be well fixed.

The invention relates to a preparation method of AFFT1 cells. RFF cells are transformed through a TCR-T technical principle, then immunosuppression target spots of transformed T cells are knocked outthrough a gene editing technology, thus the specific cytotoxic T cells are precisely protected against being inhibited in vivo, and the lethality of the T cells on tumor cells is improved.

The invention belongs to the field of a biological technology, and particularly relates to a construction method of AFFT2 cells. According to the method, the cells are reformed by a TCR-T technique, and the reformed T cells are subjected to in vitro sealing by using inhibition signal molecule antibody medicines, so that the antitumor capacity of the T cells can be effectively improved. For cells reformed by an AFFT2 scheme, the proportion for distinguishing the specific T cells of tumor antigen is 70% or above.

The invention provides an LRFFT2 cell construction method, human peripheral blood is used to sequence ctDNA or a whole exome of a tumor tissue, a mutation site is screened to predicate an epitope, andthe sequence of an expression gene of a mutation polypeptide is connected and synthesized; meanwhile, a lentiviral vector is constructed, a lentivirus is packaged, an APC (Antigen Presenting Cell) istransfected to finish the transformation of a specific LV cell, the APC is cultured in vitro together with a PBMC (Peripheral Blood Mononuclear Cell) separated from the peripheral blood, the effective polypeptide is screened, a common T cell is transformed into an RFF cell having more accurate lethality through the second impact stimulated by the accurate effective polypeptide; the transformationis conducted through the TCR-T technical principle; an immunosuppressive signal of the transformed T cell is closed in vitro by using an antibody drug, the specific lethal T cell is protected accurately against in-vivo suppression, the lethality of the T cell on a tumor cell is improved, and a more offensive and defensive LRFFT2 cell is obtained. The LRFFT2 cell is widely applied to the individualized accurate treatment of a solid tumor.

The invention provides an LRFFT1 cell construction method, human peripheral blood is used to sequence ctDNA or a whole exome of a tumor tissue, a mutation site is screened to predicate an epitope, andthe sequence of an expression gene of a mutation polypeptide is connected and synthesized; meanwhile, a lentiviral vector is constructed, a lentivirus is packaged, an APC (Antigen Presenting Cell) istransfected to finish the transformation of a specific LV cell, the APC is cultured in vitro together with a PBMC (Peripheral Blood Mononuclear Cell) separated from the peripheral blood, the effective polypeptide is screened, a common T cell is transformed into an RFF cell having more accurate lethality through the second impact stimulated by the accurate effective polypeptide; the transformationis conducted through the TCR-T technical principle; an immunosuppressive target of the transformed T cell is then knocked off through the gene editing technology, the specific lethal T cell is protected accurately against in-vivo suppression, the lethality of the T cell on a tumor cell is improved, and a more offensive and defensive LRFFT1 cell is obtained.

The invention relates to an MRFFT2 cell construction method, a mutation polypeptide is screened through the predication of an epitope, the sequence of an expression gene of the mutation polypeptide isconnected and synthesized; meanwhile, an MVA virus vector is constructed, an MVA virus is packaged, an APC (Antigen Presenting Cell) is transfected, the transformation of a specific MV cell is finished, the APC is cultured in vitro together with a PBMC (Peripheral Blood Mononuclear Cell) separated from the peripheral blood, the effective polypeptide is screened, a common T cell is transformed into an RFF cell having more accurate lethality through the second impact stimulated by the accurate effective polypeptide; the transformation is conducted through the TCR-T technical principle; an immunosuppressive signal of the transformed T cell is closed by using an antibody drug in vitro, the specific lethal T cell is protected accurately against in-vivo suppression, and the lethality of the T cell on a tumor cell is improved.

The invention belongs to the technical field of biotechnology, and particularly relates to an LFF1 cell and a preparation method thereof. According to the cell, after an antigen-presenting cell is transfected by using lentivirus for expressing antigen epitope peptide, a PBMC (peripheral blood mononuclear cell) is stimulated, then knockout of a suppressive signal molecular target is adopted for protection, and therefore the anti-tumor capacity of a T cell can be effectively improved.